COMMUNIQUÉS West-GlobeNewswire

Trinity Biotech Announces Q3 2024 Financial Results
15/11/2024
Q3 2024 total revenue of $15.2 million grew +3% Y/Y based on strong demand and output in the TrinScreen HIV business Point-of-Care product revenue of $4.3 million grew 60% Y/Y Reiterates guidance to achieve [...]
Outset Medical to Present at the 2024 Stifel Healthcare Conference
15/11/2024
SAN JOSE, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, [...]
Scientific Industries Reports Third Quarter 2024 Financial Results
15/11/2024
BIOPROCESSING OPERATIONS RECORDS 3 CONSECUTIVE QUARTERS OF REVENUE GROWTH OPERATIONAL EFFICIENCIES CUT QUARTER AND YTD NET LOSSES BY 46% AND 34% TWO MAJOR NEW PRODUCTS TO LAUNCH IN Q1 2025 Investor Call to be held [...]
Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024
15/11/2024
PALO ALTO, Calif. , Nov. 15, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non- [...]
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
15/11/2024
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for [...]
Samsung Bioepis Receives Positive CHMP Opinion for Denosumab Biosimilars, OBODENCE™ and XBRYK™
15/11/2024
OBODENCE™ and XBRYK™ recommended for approval by the European Medicines Agency for all indications referencing Prolia and Xgeva, respectively INCHEON, South Korea, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., [...]
Sienna Announces November Dividend
15/11/2024
MARKHAM, Ontario, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
15/11/2024
SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and [...]
Wave Life Sciences to Present at Jefferies London Healthcare Conference
15/11/2024
CAMBRIDGE, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, [...]
SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer
15/11/2024
DENVER, Nov. 15, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on [...]
Safety Shot Expands Retail Footprint with Major Grocery Chain in US Southwest
15/11/2024
Company's Rapid Alcohol-Reducing Beverage, Sure Shot, to be Sold in 192 Stores Across Nevada, Arizona, and California JUPITER, Fla., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or “ [...]
Biotricity Achieves Improved Margins and Efficiencies, and Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2025
15/11/2024
Company achieved positive cash flow in September on a current operating basis, before paying interest, dividends and amortization; management expects to continue to see cash flows improve Company reports Q2-FY25 revenue [...]
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
15/11/2024
New post-hoc analyses reinforce pegozafermin’s potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpoints SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- [...]
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus
15/11/2024
NAPLES, Fla., Nov. 15, 2024 (GLOBE NEWSWIRE) -- via IBN – HealthLynked Corp. ( OTCQB: HLYK ), a leader in healthcare networking and technology innovation, today announced financial results for the three- and nine-months [...]
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
15/11/2024
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from [...]
UPDATED – Inspire Medical Systems, Inc. to Present at Jefferies London Healthcare Conference
15/11/2024
MINNEAPOLIS, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive [...]
InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
15/11/2024
JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Committee for [...]
Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update
15/11/2024
MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression after one or more [...]
Osteal Therapeutics Announces Positive 12-Month Results from the APEX Clinical Trial Program at the 2024 American Association of Hip and Knee Surgeons (AAHKS) Annual Meeting
14/11/2024
Outcomes at 12 months demonstrate a statistically significant net treatment effect of 19% compared to the standard of care two-stage exchange arthroplasty and highlight a 71% reduction in PJI burden DALLAS, Nov. 14, [...]

Pages